Last reviewed · How we verify
Sitaglitpin
At a glance
| Generic name | Sitaglitpin |
|---|---|
| Also known as | Januvia |
| Sponsor | University Health Network, Toronto |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 (PHASE1, PHASE2)
- The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |